Tags

Type your tag names separated by a space and hit enter

Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients.
Int Urol Nephrol. 2018 Nov; 50(11):2073-2079.IU

Abstract

PURPOSE

The current study was conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on glycemic control and markers of lipid profiles risk in diabetic hemodialysis (HD) patients.

METHODS

This randomized, double blind, placebo-controlled clinical trial was performed among 60 diabetic HD patients. Subjects were randomly allocated into two groups to take either 120 mg/day of CoQ10 supplements or placebo (n = 30 each group) for 12 weeks.

RESULTS

After 12 weeks of intervention, CoQ10 supplementation, compared with the placebo, resulted in a significant decrease in serum insulin concentrations (- 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (- 0.9 ± 2.1 vs. + 1.2 ± 3.0, P = 0.002), and significant increase in the quantitative insulin sensitivity check index (+ 0.009 ± 0.01 vs. - 0.02 ± 0.05, P = 0.003). In addition, a trend toward a greater decrease in serum triglycerides (- 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-cholesterol levels (- 0.9 ± 10 vs. + 3 ± 9, P = 0.078) was observed in the CoQ10 group compared to the placebo group. We did not observe any significant effect of CoQ10 supplementation on fasting glucose, HbA1c and other lipid profiles compared with the placebo.

CONCLUSIONS

Overall, our study supported that CoQ10 supplementation to diabetic HD patients for 12 weeks had beneficial effects on markers of insulin metabolism, but did not affect fasting glucose, HbA1c, and lipid profiles. Clinical registration http://www.irct.ir : IRCT2016081811763N30.

Authors+Show Affiliations

Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. askari@mui.ac.ir.Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.Isfahan Endocrine and Metabolism Research Center, Isfahan, Iran. Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30251010

Citation

Fallah, Melika, et al. "Clinical Trial of the Effects of Coenzyme Q10 Supplementation On Glycemic Control and Markers of Lipid Profiles in Diabetic Hemodialysis Patients." International Urology and Nephrology, vol. 50, no. 11, 2018, pp. 2073-2079.
Fallah M, Askari G, Soleimani A, et al. Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. Int Urol Nephrol. 2018;50(11):2073-2079.
Fallah, M., Askari, G., Soleimani, A., Feizi, A., & Asemi, Z. (2018). Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. International Urology and Nephrology, 50(11), 2073-2079. https://doi.org/10.1007/s11255-018-1973-z
Fallah M, et al. Clinical Trial of the Effects of Coenzyme Q10 Supplementation On Glycemic Control and Markers of Lipid Profiles in Diabetic Hemodialysis Patients. Int Urol Nephrol. 2018;50(11):2073-2079. PubMed PMID: 30251010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. AU - Fallah,Melika, AU - Askari,Gholamreza, AU - Soleimani,Alireza, AU - Feizi,Awat, AU - Asemi,Zatollah, Y1 - 2018/09/24/ PY - 2018/02/12/received PY - 2018/08/23/accepted PY - 2018/9/27/pubmed PY - 2019/3/21/medline PY - 2018/9/26/entrez KW - Coenzyme Q10 supplementation KW - Glycemic control KW - Hemodialysis KW - Lipid profiles SP - 2073 EP - 2079 JF - International urology and nephrology JO - Int Urol Nephrol VL - 50 IS - 11 N2 - PURPOSE: The current study was conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on glycemic control and markers of lipid profiles risk in diabetic hemodialysis (HD) patients. METHODS: This randomized, double blind, placebo-controlled clinical trial was performed among 60 diabetic HD patients. Subjects were randomly allocated into two groups to take either 120 mg/day of CoQ10 supplements or placebo (n = 30 each group) for 12 weeks. RESULTS: After 12 weeks of intervention, CoQ10 supplementation, compared with the placebo, resulted in a significant decrease in serum insulin concentrations (- 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (- 0.9 ± 2.1 vs. + 1.2 ± 3.0, P = 0.002), and significant increase in the quantitative insulin sensitivity check index (+ 0.009 ± 0.01 vs. - 0.02 ± 0.05, P = 0.003). In addition, a trend toward a greater decrease in serum triglycerides (- 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-cholesterol levels (- 0.9 ± 10 vs. + 3 ± 9, P = 0.078) was observed in the CoQ10 group compared to the placebo group. We did not observe any significant effect of CoQ10 supplementation on fasting glucose, HbA1c and other lipid profiles compared with the placebo. CONCLUSIONS: Overall, our study supported that CoQ10 supplementation to diabetic HD patients for 12 weeks had beneficial effects on markers of insulin metabolism, but did not affect fasting glucose, HbA1c, and lipid profiles. Clinical registration http://www.irct.ir : IRCT2016081811763N30. SN - 1573-2584 UR - https://www.unboundmedicine.com/medline/citation/30251010/Clinical_trial_of_the_effects_of_coenzyme_Q10_supplementation_on_glycemic_control_and_markers_of_lipid_profiles_in_diabetic_hemodialysis_patients_ L2 - https://doi.org/10.1007/s11255-018-1973-z DB - PRIME DP - Unbound Medicine ER -